Market PotentialThe Cancerguard test represents a largely untapped addressable market of $25 billion, which could provide significant growth opportunities for Exact Sciences.
Product LaunchExact Sciences launched its Multi-Cancer Early Detection (MCED) test, Cancerguard, which addresses approximately 70% of cancers lacking a screening solution, potentially unlocking a $25 billion market.
Revenue ExpectationsManagement raised full-year 2025 revenue guidance by $55 million at the midpoint, reflecting strong future revenue expectations.